Abemaciclib
- Generic Name
- Abemaciclib
- Brand Names
- Verzenio, Verzenios
- Drug Type
- Small Molecule
- Chemical Formula
- C27H32F2N8
- CAS Number
- 1231929-97-7
- Unique Ingredient Identifier
- 60UAB198HK
- Background
Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the treatment of HR-positive and HER2-negative a...
- Indication
适应症为:⑴单药治疗接受过内分泌疗法和化疗后疾病进展的 ER+/HER2-晚期或转移性乳腺癌；⑵或联合氟维司群，二线治疗接受过内分泌疗法后疾病进展的 ER+/HER2-晚期或转移性乳腺癌；⑶联合芳香酶抑制剂作为 ER+/HER2-绝经后女性晚期或转移性乳腺癌的初始内分泌疗法。
- Associated Conditions
- HR+, HER2-, Advanced Breast Cancer, Early Hormone Receptor Positive, HER2/Neu Negative Node Positive Breast Cancer, Metastatic HR + HER2 - breast cancer
- Associated Therapies
- -
A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread
- First Posted Date
- 2014-04-03
- Last Posted Date
- 2020-01-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 132
- Registration Number
- NCT02102490
- Locations
- 🇺🇸
Texas Oncology-Plano West, Plano, Texas, United States
🇺🇸Northwest Cancer Specialists PC, Vancouver, Washington, United States
🇺🇸Univ of California San Francisco, San Francisco, California, United States
A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2014-03-06
- Last Posted Date
- 2020-09-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 142
- Registration Number
- NCT02079636
- Locations
- 🇺🇸
Highlands Oncology Group, Fayetteville, Arkansas, United States
🇺🇸Indiana Cancer Pavilion, Indianapolis, Indiana, United States
🇺🇸The West Clinic, Germantown, Tennessee, United States
Study of LY2835219 for Mantle Cell Lymphoma
- First Posted Date
- 2012-12-03
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 28
- Registration Number
- NCT01739309
- Locations
- 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ulm, Germany
A Study of LY3023414 in Participants With Advanced Cancer
- First Posted Date
- 2012-08-01
- Last Posted Date
- 2022-04-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 156
- Registration Number
- NCT01655225
- Locations
- 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸Penn Presbyterian Medical Center, Philadelphia, Pennsylvania, United States
🇮🇹Azienda Ospedaliero - Universitaria S. Luigi Gonzaga, Orbassano, Torino, Italy
A Phase 1 Study of LY2835219 In Participants With Advanced Cancer
- First Posted Date
- 2011-07-14
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 225
- Registration Number
- NCT01394016
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, San Antonio, Texas, United States
🇺🇸For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santa Monica, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.